Supporting Information

Suppression of *Forkhead Box Protein O1 (FOXO1)* Transcription Factor May Promote Adrenocortical Tumorigenesis

Authors:

Adam Stenman\textsuperscript{1,2,*}, Timothy Murtha\textsuperscript{1,2}, Reju Korah\textsuperscript{1,2}, Tobias Carling\textsuperscript{1,2}

Affiliations:

\textsuperscript{1}Yale Endocrine Neoplasia Laboratory, Yale School of Medicine, New Haven, Connecticut, USA.

\textsuperscript{2}Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.

Correspondence:

Tobias Carling, MD, PhD, FACS

Section of Endocrine Surgery

Department of Surgery

Yale Endocrine Neoplasia Laboratory

Yale School of Medicine

333 Cedar Street, TMP FMB130A,

P.O. Box 208062

New Haven, CT 06520,

U.S.A.

Tel: +1-203-737-2036, Fax: +1-203-737-4067

Email: tobias.carling@yale.edu
Figure 1S. Results from transfection verification experiments. (A) Column chart comparing the FOXO1 relative expression as measured with qRT-PCR in SW-13 cells treated with Lipofectamine only (SW-L), Negative scrambled siRNA (SW-NS) and siRNA targeting FOXO1 (SW-siA and SW-siC). (B) Western Blot membrane with FOXO1 antibody and protein from SW-L cells, SW-NS, SW-siA and SW-siC.